Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Kiren Kresa-Reahl"'
Autor:
Crystal Watson, Dhanalakshmi Thirumalai, Arie Barlev, Eddie Jones, Sasha Bogdanovich, Kiren Kresa-Reahl
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 1961-1979 (2023)
Abstract Introduction Much of the current literature on treatment patterns and disability progression in multiple sclerosis (MS) does not distinguish between the relapsing–remitting and progressive subtypes (including primary [PPMS] and secondary p
Externí odkaz:
https://doaj.org/article/e5bed912d1c24028a5e2841dc4079259
Publikováno v:
Neurology and Therapy. 11:725-739
Fatigue is one of the most common and debilitating symptoms of multiple sclerosis (MS) but is challenging to assess and has not been comprehensively characterized in patients with progressive MS. This study aimed to (1) obtain qualitative evidence fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::804e047e27f9f5791582766ec2cef39d
https://doi.org/10.1007/s40120-022-00337-9
https://doi.org/10.1007/s40120-022-00337-9
Autor:
Kiren Kresa-Reahl, Pavle Repovic, Irene Koulinska, Ray Su, Stanley Cohan, Derrick Robertson, Robin Avila, Jason P. Mendoza
Publikováno v:
Neurology and Therapy
Introduction This post hoc subset analysis of RESPOND evaluated the effectiveness of dimethyl fumarate (DMF) 240 mg twice daily in patients with relapsing multiple sclerosis (RMS) after suboptimal response to glatiramer acetate (GA; “first switch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c068c32232fcce739fc659bc5bcb145e
http://europepmc.org/articles/PMC8140000
http://europepmc.org/articles/PMC8140000
Autor:
Bhupendra O. Khatri, Matt Mandel, Kiren Kresa-Reahl, Chakkarin Burudpakdee, Keith R. Edwards, Jeffrey Chavin, Robert Zivadinov, Bianca Weinstock-Guttman, Karthinathan Thangavelu, Stanley Cohan, Michael G. Dwyer, Niels Bergsland
Publikováno v:
Journal of Comparative Effectiveness Research. 8:305-316
Aim: Head-to-head clinical trials of teriflunomide (TFM) versus dimethyl fumarate (DMF) have not been conducted. Objectives: To compare the real-world effectiveness of TFM versus DMF. Methods: Anonymized data were collected from patients with relapsi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdcf46488f3e5b5274378662eb4287a8
https://doi.org/10.2217/cer-2018-0135
https://doi.org/10.2217/cer-2018-0135
Autor:
Pavle Repovic, Jason P. Mendoza, Macaulay Okwuokenye, Leslie Meltzer, Derrick Robertson, Kiren Kresa-Reahl
Publikováno v:
Clinical Therapeutics. 40:2077-2087
The goal of this study was to evaluate clinical outcomes and patient-reported outcomes (PROs) over 12 months in patients with relapsing multiple sclerosis (RMS) who switched from glatiramer acetate (GA) to delayed-release dimethyl fumarate (DMF) 240
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2daf041b696d67c58992f041d5627b2
https://doi.org/10.1016/j.clinthera.2018.10.011
https://doi.org/10.1016/j.clinthera.2018.10.011
The impact of translational research on the development of therapeutic agents for multiple sclerosis
Autor:
Stanley L. Cohan, Elisabeth B. Lucassen, Kiren Kresa-Reahl, Meghan Romba, Kyle Smoot, Stefanie N. Linch
Publikováno v:
Neurotherapeutics in the Era of Translational Medicine ISBN: 9780128164754
Multiple sclerosis (MS) is a severe, progressive, and disabling disease, for which there were no significant disease-modifying therapies until 25 years ago. The intervening years have witnessed the rapid expansion of medications that confer clinicall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2ef806444cc36b0e03c475d2cd7ba20
https://doi.org/10.1016/b978-0-12-816475-4.00010-0
https://doi.org/10.1016/b978-0-12-816475-4.00010-0
Autor:
Karen Aboody, Olubankole Aladesuyi Arogundade, Giovanni Appendino, Weiqi Bao, Marco A.S. Baptista, Danielle Beaulieu, Frank Bennett, Emma Brand, Don Cleveland, Stanley L. Cohan, Jonavelle Cuerdo, Jim DeMesa, David L. Ennist, Meryem Guler, Nada Hindiyeh, Hanna Hovren, Yiyun Henry Huang, Hongmei Jia, Jie Jiang, Brian K. Kaspar, Petra Kaufmann, Randall Kaye, Jeffery W. Kelly, Mike Keymer, Doo Yeon Kim, Kiren Kresa-Reahl, Ikjae Lee, Melanie Leitner, Stefanie N. Linch, Elisabeth B. Lucassen, Timothy Miller, Rachael Mooney, Gaetano Morello, Eduardo Muñoz, Michael Murray, Hoi Wa Ngai, Joseph Park, Dustin Pierce, Jana Portnow, Evan T. Powers, Luisa Quinti, John Ravits, Meghan Romba, Rajesh Sampath, S. Pablo Sardi, Mark Schactman, Mohammad Shahnawaz, Richard A. Smith, Kyle E. Smoot, Claudio Soto, Clive N. Svendsen, Soshana P. Svendsen, Rudolph E. Tanzi, Albert A. Taylor, Gil I. Wolfe, Clinton B. Wright, Gerald Yakatan, Neta Zach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc3421a84af02dbf2e438ec95985c79e
https://doi.org/10.1016/b978-0-12-816475-4.09992-4
https://doi.org/10.1016/b978-0-12-816475-4.09992-4
Autor:
Robert Garland, Crystal Watson, Ning Wu, Kyle Smoot, Stanley Cohan, Wei-Shi Yeh, Kiren Kresa-Reahl
Publikováno v:
Advances in Therapy
Introduction This study was designed to assess real-world outcomes of patients with multiple sclerosis (MS) who were stable on interferon (IFN) beta therapy in the year prior to switching to another IFN beta therapy versus those who continued on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28bcdaa2758416ed9d390f593d363812
https://doi.org/10.1007/s12325-018-0799-5
https://doi.org/10.1007/s12325-018-0799-5
Autor:
Cohan, Stanley L, Edwards, Keith, Lucas, Lindsay, Gervasi-Follmar, Tiffany, O’Connor, Judy, Siuta, Jessica, Vineetha Kamath, Garten, Lore, Chiayi Chen, Thomas, James, Smoot, Kyle, Kiren Kresa-Reahl, Kateri J Spinelli
Supplemental material, Supplemental Material1 for Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy by Stanley L Cohan,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7185bf3c266231de1f629b79593152e0
Autor:
Chiayi Chen, Lore Garten, Judy O'Connor, Jessica Siuta, Kateri J. Spinelli, Vineetha Kamath, Keith R. Edwards, Kiren Kresa-Reahl, Lindsay Lucas, Kyle Smoot, James Thomas, Stanley Cohan, Tiffany Gervasi-Follmar
Publikováno v:
Multiple Sclerosis Journal-Experimental, Translational and Clinical
Background Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies. Objective To assess the efficacy of teriflunomide fol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::281ad74312f81a02300aad0a7e8fceeb
http://europepmc.org/articles/PMC6350141
http://europepmc.org/articles/PMC6350141